-- シノ・バイオファーマシューティカル（香港証券取引所：1177）傘下の新薬M701の承認申請が、中国国家薬品監督管理局に受理されたことが、木曜日に香港証券取引所に提出された書類で明らかになった。 この薬剤は、同社の子会社である嘉泰天青製薬集団が、進行性上皮性悪性腫瘍による悪性腹水の治療薬として共同開発した。
Related Articles
International
US Initial Jobless Claims 200,000 Vs. Expected 205,000, Prior 190,000
Equities
Adnoc Tankers Shut Signals to Cross Hormuz
Abu Dhabi National Oil Co., or Adnoc, LNG tankers reportedly switched off signals to cross the Strait of Hormuz.Bloomberg News reported Thursday, citing analysis of vessel-tracking data and sources, that at least two Adnoc tankers crossed the strait by going dark.Adnoc did not immediately respond to a request for comment from.
$^FADGI
Research
AlphaMena Upgrades Al-Babtain Power and Telecommunication to Add, Boosts PT
AlphaMena on Thursday upgraded power and telecommunications products company Al-Babtain Power and Telecommunication (SASE:2320) to add from reduce and increased its price target to 75.60 Saudi riyals from 66.30 riyals.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$SASE:2320